Clinical Trial Detail

NCT ID NCT03057613
Title A Study of the Addition of Pembrolizumab to Postoperative Radiotherapy in Resected High Risk Cutaneous Squamous Cell Cancer of the Head and Neck
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Case Comprehensive Cancer Center
Indications

head and neck squamous cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.